Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.4K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.4K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.1K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.1K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

636
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
636
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

2.7K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.7K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple spinal muscular atrophy disease-modifying effects of a Hspa8G470R synaptic chaperone variant.

Brain : a journal of neurology·2026
Same author

Cardiac defects in spinal muscular atrophy and the role of SMN in cardiomyocyte homeostasis.

bioRxiv : the preprint server for biology·2026
Same author

Protein-stabilizing and neurotransmission-potentiating activities of a synaptic chaperone modify spinal muscular atrophy in model mice.

bioRxiv : the preprint server for biology·2026
Same author

The role of machine learning in autism spectrum disorder assessment and management.

Pediatric research·2025
Same author

Peripheral defects precede neuromuscular pathology in the <i>Smn<sup>2B/-</sup></i> mouse model of spinal muscular atrophy.

Journal of neuromuscular diseases·2025
Same author

Impact of liver-specific survival motor neuron (SMN) depletion on central nervous system and peripheral tissue pathology.

eLife·2025

Related Experiment Video

Updated: Sep 22, 2025

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

61.6K

Curing SMA: Are we there yet?

Aoife Reilly1,2,3, Lucia Chehade1,2,3, Rashmi Kothary4,5,6,7,8

  • 1Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Gene Therapy
|May 25, 2022
PubMed
Summary

Spinal Muscular Atrophy (SMA) treatments have improved patient survival, but challenges like varied responses remain. Further research is crucial to find a complete cure for this severe neuromuscular disease.

More Related Videos

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.2K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.7K

Related Experiment Videos

Last Updated: Sep 22, 2025

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

61.6K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.2K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.7K

Area of Science:

  • Neurology
  • Genetics
  • Pharmacology

Background:

  • Spinal Muscular Atrophy (SMA) is a severe neuromuscular disease caused by the loss or deletion of the Survival Motor Neuron 1 (SMN1) gene.
  • The SMN1 gene produces the SMN protein, vital for motor neuron development and survival.

Purpose of the Study:

  • To review current therapies for SMA, including nusinersen, onasemnogene abeparvovec, and risdiplam.
  • To discuss the limitations of existing SMA treatments and identify gaps in care.
  • To highlight areas for future research to achieve a definitive cure for SMA.

Main Methods:

  • Literature review of current SMA therapies.
  • Analysis of treatment outcomes and patient responses.
  • Identification of challenges and unmet needs in SMA management.

Main Results:

  • Approved therapies have extended survival and improved outcomes for SMA patients.
  • Significant variability exists in patient response to current treatments.
  • Challenges persist, including suboptimal treatment efficacy and the need for a definitive cure.

Conclusions:

  • While current SMA therapies offer benefits, they do not represent a complete cure.
  • Addressing treatment variability and response is critical for optimizing patient outcomes.
  • Continued research is essential to overcome existing limitations and ensure the best possible future for individuals with SMA.